Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATTERN trial of aflibercept 8 mg treat-and-extend in diabetic macular edema
KCT0012571Phase 4Not yet recruiting
- Sponsor
- Bayer
- Start
- Sep 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Bayer. Primary endpoint: Mean change from baseline to Week 48 in BCVA. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on KCT0012571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012571.